EraGen Biosciences will use Applied BioCode's Bar-Coded Magnetic Bead Technology and CE-marked BioCode-1000 analyzer in the development and clinical laboratory use of multiplexed infectious disease and genetic tests.
EraGen will combine its MultiCode® platform chemistry for both real-time PCR and multiplex PCR-based assays with Applied BioCode’s technology and products under a strategic technology partnership and license agreement signed by the companies.
"We look forward to commercializing molecular diagnostics that address not only customers needing real-time molecular testing but also those in the growing segment that need highly-multiplexed in vitro diagnostics,” remarks Irene Hrusovsky, M.D., EraGen’s chairman and CEO. "Our relationship with Applied BioCode will help us reach those goals."
EraGen develops, manufactures, and markets molecular reagent products used in DNA- and RNA-based testing for early detection of infectious diseases and genetic-based conditions. In December the company won a $244,500 grant through the federal Qualifying Therapeutic Discovery Project Program for expansion of its manufacturing operations to meet growing demand for its MultiCode® molecular diagnostic products.